Jui Teng Lin^{1}*, Kuo Ti Chen^{2,3} and Hsia Wei Liu^{4}
^{1} Chairman & CEO of New Vision Inc Taipei, Taiwan
^{2} Graduate Institute of Applied Science and Engineering, Fu Jen Catholic University, Taiwan
^{3} PhotoDynamic C_{0}, Taiwan
^{4} Department of Life Science, Fu Jen Catholic University, Taiwan
*Corresponding author:Jui Teng Lin, Chairman and CEO of New Vision Inc, Taipei, Taiwan
Submission: October 06, 2018;Published: October 10, 2018
ISSN:2637-773X
Volume2 Issue1
The role of oxygen, cell killing threshold dose and efficacy improvement of anti-cancer via type-II phototherapy are analyzed by both analytic formulas and numerical data. Higher initial photoinitiator (PS) concentration (C_{0}) and/or light intensity (I_{0}) has a faster efficacy, due to faster depletion of PS and oxygen concentration. Without the external oxygen supply, higher C_{0} or I_{0} produces more efficient singlet oxygen, resulting a higher transient efficacy, but they reach the same steady-state value when oxygen is completely depleted. With the external oxygen supply, higher efficacy (with no steady-state limitation), or lower cell viability are achieved. The overall efficacy may be enhanced by resupply of PS or oxygen during the light exposure.
Keywords: Modeling; Phototherapy; Kinetic; Anti-cancer; Singlet oxygen; Efficacy
Photodynamic therapy (PDT) is an effective method for anticancer via oxygen-mediated type-II mechanism, where the cytotoxic effect of PDT to tumor tissue is resulted by the generation of singlet oxygen. Efficacy of PDT is mainly influenced by: the concentration of PS drug accumulated into the cells, molecular oxygen in tissue, the light dose, intensity and dose (fluence) [1]. High concentrations of singlet oxygen can lead to necrotic cell death. In contrast, low concentrations lead to cell survival and increase the metabolism; whereas medium singlet oxygen concentrations lead to initiation of apoptosis or autophagy [2]. Therefore, the threshold light dose and singlet oxygen dose play the important role in PDT for anticancer. Recently, the singlet oxygen threshold dose, and the dosedependence cell viability curves of human cancer cells of K562 and Hela after red-light irradiation of Radachlorin were reported in vivo [3].
The kinetics and macroscopic modeling of PDT have been reported for anti-cancer using an oxygen-mediated type-II PDT [4-8] and more recently, for corneal diseases using non-oxygenmediated type-I PDT [9,10] since, the earlier work of Foster et al. [4] in 1991. Most of the previous modeling [4-8] have ignored the dynamic of light intensity and the depth-dependent profile PS and light intensity, where the exact modeling requires numerical simulations, especially when both type-I and type-II coexist [10- 12].
This study will theorize the role of concentration of PS and oxygen, rate constant, oxygen external source term, light dose, intensity and exposure time in the efficacy and threshold dose of anti-cancer via oxygen-mediated type-II mechanism. We will also analyze the measured in vitro singlet oxygen threshold dose reported by Klimenko et al. [3]. Both analytic formulas (for the first time) and numerical calculations will be presented.
The kinetics of PDT for corneal collagen crosslinking was previously reported by Lin et al. [13] using UVA (365nm) initiated riboflavin solution as the photosensitizer. The three pathways kinetics are revised for a more general polymer system and briefly summarized as follows [12]. In type-I pathway, the excited PS triplestate (T3) can interact directly with the substrate (A); or with the ground state oxygen (O2) to generate a superoxide anion (O-), which further reacts with oxygen to produce reactive oxygen species (ROS). In comparison, in type-II pathway, T3 interacts with (O2) to form a reactive singlet oxygen (O*). In general, both type-I and type-II reactions can occur simultaneously, and the ratio between these processes depends on the types and the concentrations of PS, substrate and oxygen, the kinetic rates involved in the process [10].
A set of macroscopic kinetic (quasi steady-state) equation for the concentration of PS ground-state, C(z,t), and the ground state oxygen molecule [O2] was constructed [7,8,10].
where b=aqI (z,t); a=83.6wa’; w is the light wavelength; a’ and b’ are the molar extinction coefficient of the initiator and the photolysis product, respectively; Q is the absorption coefficient of the monomer and the polymer repeat unit.
Eq. (1.a) includes the type-I term,
, and type-II; d is a low concentration correction related to the diffusion of singlet oxygen [4,7]. [A] is the substrate concentration. q is the triplet state [T] quantum yield given by with s_{1} and s_{2} are the fraction of [O2] converted to the singlet oxygen and other ROS, respectively, in type-I and type-II [7].In Eq. (1.c) we have included the light intensity in the polymer given by a time-dependent Beer-Lambert law [13]. Eq. (1.b) includes the oxygen source term P( z,t) = p( 1− [O2] / [0_{O}]) , with a rate constant p to count for the situation when there is an external continuing supply, or nature replenishment (at a rate of p), besides the initial oxygen, [0_{O}], in the cells [7].
We note that Eq. (1) was also presented by Gkigkitzis et al. [6], Zhu et al. [7,8] and Klimenko et al. [3] for the anti-cancer kinetics. However, they have assumed a constant light intensity, i.e., A’(z,t) is a constant in Eq. (1.d). They also ignored the contribution from the type-I term, k_{8}[A], since type-II is dominant in their anti-cancer process. The previous model [6-10] have also ignored the dynamic of light intensity given by Eq. (1.c) and the depth-dependent profile PS and light intensity. Exact solutions of Eq. (1) require numerical simulations, specially when both type-I and type-II coexist [10- 12]. For comprehensive analysis and empirical formulas, we will present analytic methods and focus on type-II efficacy.
The normalized photo-polymerization efficacy defined by Ceff =1− [A] / [A]_{O} = 1− exp −S , with S-function, for a type-II dominant process, given by [10].
where f = k_{72}[ A] / k_{12} , proportional to the substrate concentration [A]. We note that the S function is proportional to the cumulative singlet oxygen generation, [^{1}O_{2}], multiplied by a factor f, and [^{1}O_{2}] =bK’CG.
For analytic formulas, three methods are available for the effective extinction coefficient: (I) using the mean light intensity given by I’(z) = 0.5(I1+ I 2) , with Ij = I_{0}exp (−Ajz) ; A1 = 2.3aC_{0} +Q , and 2 0 A = 2.3bC +Q; (ii) a mean (over z) C’(t), A(t) = 2.3(a − b)C’(t) +Q , in which C’(t)is a decreasing function of time, such that l (z,t) is an increasing function of time; and (iii) using a time-dependent light intensity given by
where t* is the crosslink steady-state time (t*) defined by when the PS concentration is depleted to 0.018 (or 1/e4) of its initial value, given by t* = 4m’ / [a’I ( z, t )] , which is inverse proportional to the light intensity. we will use an effective A(z,t) or its mean value, such that A’(z,t) becomes time-independent in solving Eq. (1). The effective extinction coefficient is given by [12], A = 2.3a’m (1− 0.25z / D) C_{0} +Q . with m is a numerical fit parameter, m=0.4 to 0.6 depending on the value of a’ and b’.In Eq. (1.a), for type-I dominant case (with g’<< g), C(z,t) has a simple exponential decaying function of bK’, if b (or light intensity) is not time-dependent, given by
. However, for general case with time-dependent light intensity, C(z,t) has a more complex decaying function and requires a numerical solution. For the case of simple exponential decaying, the value of bK’ = (aqgK’) I (z,t ) , may be empirically found if C(z,t) is measured.Type-II process is much more complex than type-I due to the complex function of G(z,t) which depends on oxygen concentration and requires numerical solutions [12,13]. For analytic formula in type-II dominant case (with g’>>g), and for the low concentration correction, d>>C_{0}, we assume an approximated PS concentration given by a similar form as type-I, C (z,t) = C_{0} Fexp −Bt , with B = dbK’,b = aqI (z) ; the oxygen concentration, [O2], may be obtained by solution of Eq. (1.b) which leads to the solution of a nonlinear equation as follows:
and Y1 = [O2] + kln[O2], Y0 = [O_{0}] + kln[O_{0}.] . Eq. (4) still needs numerical solution for the oxygen concentration, [O2], and will be shown later. Approximate solution is given by [O2] = [O_{0}] – mt, m = f ’bC , with f’ is a fit parameter. Therefore, G=N –N’ t, with
. . The secondorder PS concentration then becomes , with B_{1} t = bK (N − 0.5N’t) , which reaches its steady-state (C’), when oxygen is completely depleted, or [O2]=0 at t=t’, and the steady-state given byWe note that higher C_{0} leads to faster depletion of oxygen, as shown by Eq. (4), and has a smaller t’, which also gives smaller value of B’t’ leading to a larger C’. This feature will be justified by our numerical results later. Moreover, C(t) is decreasing function less strong than a simple exponential rate of bKNt due to the negative term of -0.5N’t^{2}.
Using he analytic functional forms for C(t), the time integral of Eq. (2) gives us, for k<< [O0] and P=0,
with I’=0.5(I_{1}+I_{2}) is a mean light intensity, and HO is a highorder term.
Eq. (5) shows that the type-II efficacy is an increasing function of I_{0}C_{0} [O0]; It has a transient state (with E1=t) proportional to the light dose, I_{0}t; and steady-state is only dose-dependent (for the case of P=0), to be justified by numerically later.
The following numerical results are for type-II (with g<
Eq. (1.a) shows that when oxygen is depleted, with [O2]=0, G=0, and C(z,t) reaches its steady state constant value (for the type-II dominant case), bK’/B. This implies that C(z,t) and [O2] have the same decaying rate to reach their steady states, which also define the maximum efficacy, or minimum cell viability. We will present the role of these parameters: C_{0}, [O0], p, K’, I_{0}, light dose, or exposure time as follows. Referring to Figure 1 to 4 for the time profiles of oxygen, PS concentration, S-function and cell viability (CV), the following important features are summarized.
Figure 1:Normalized PS concentration, C(t), vs. time for various initial PS concentration, C0= (5,10,15)uM (for curve 1,2,3) and fixed value of [O]0=100uM, K’=0.0025 (1/um), and p=0, for light intensity I0= 20 and 50 mW/cm2, for Figure (A) and (B), respectively.
Figure 2:Normalized oxygen concentration, y=[O2], vs. time associate to Figure 1.
Figure 3:Cell viability (CV) vs. time associate to Figure 1 (for p=0).
Figure 4:Same as Figure 1 for the normalized PS concentration vs. time but for p=0.2 (uM/s), for light intensity I0= 20 and 50 mW/cm2, for Figure (A) and (B), respectively.
The role of C_{0} and I_{0}: The role of initial PS concentration (C_{0}) and light intensity (I_{0}), are shown by (Figure 1), the normalized PS concentration vs. time for the case of no external oxygen supply (or p=0) for various initial PS concentration, C_{0}= (5,10,15)uM, and fixed value of [O_{0}] =100 uM , K’ = 0.0025 (1/ uM ) , aq = 0.02(cm^{2} / mW / s) , with intensity I = (20, 50) mW / cm^{2} . The oxygen concentration profiles are shown in (Figure 2); and cell viability, defined by CV=1- exp(-S) is shown in (Figure 3). Higher C_{0} and/or light intensity (I_{0}) result a faster PS and oxygen depletion leading to a higher efficacy, or lower CV. As shown by (Figure 3), CV reaches approximately 0.2 at 400 seconds, fo I = 20 mW / cm^{2} , comparing to 200 seconds for I = 20 mW / cm^{2} , and both have the same dose of 4 J/cm^{2}. Therefore, the CV is mainly determined by the light dose and follow the socalled Bunsen Roscoe law (BRL) for the case of p=0 in the type-II process. This BRL is slightly revised when p>0, in contrast to type-I efficacy which follows a non-BRL.
As shown by (Figure 2), without the external oxygen supply (with p=0), oxygen is depleted by a negative slope proportional to bC_{0}, referring to Eq. (5). Therefore, higher C_{0} and/or light intensity (I_{0}) has a faster depletion rate. As shown by (Figure 1), C(t) reaches a steady-state (C’) when oxygen is completed depleted; noting that C’ is higher for higher C_{0}, as also shown by our analytic Eq. (4), for a smaller t’ (or faster oxygen depletion). Moreover, C(t) is a decreasing function less strong than a simple exponential rate of bKNt due to the negative term of -0.5N’t^{2}, as predicted by Eq. (4).
Profiles for p>0: With the external oxygen supply (with p>0), above feature changed significantly, comparing to (Figure 1), that the PS concentration shown by (Figure 4) does not reach a steadystate, but continuously decreases due to the replenishing oxygen, as shown by (Figure 4), (Figure 5) shows the oxygen profiles, in which higher C_{0} and/or light intensity (I_{0}) results to faster oxygen and PS depletion, and leading to lower CV, as shown by (Figure 5).
Figure 5:Normalized oxygen concentration vs. time associate to Figure 4 (for p=0.2 uM/s).
Figure 6:Cell viability for p=0 and p=0.4 (uM/s) shown by (A) and (B), respective; also shown are the threshold time (t*) to reach a cell viability CV*< 25%.
The threshold dose: Figure 6 show the cell viability for p=0 and p=0.4 (uM/s), respective. They show that the cell viability, defined by CV=exp(-S), is lower for higher C_{0} and/or light intensity (I_{0}). Moreover, with p>o, external oxygen offers lower CV, or better cell killing. It also shows the threshold dose E*=I_{0}t* (or time t* for a fixed light intensity) to reach a cell viability CV*<25%, is higher for smaller C_{0} and/or I_{0}, in consistent with the measured data of Klimenko et al. [5], in which CV also follows out formula of CV=exp(-S), referring to their (Figure 5). Moreover, (Figure 6) also shows that the product of C_{0}E* follows BRL for the case of p=0, whereas BRL is invalid for the case of p>0 (with external oxygen supply).
Clinically, the external oxygen supply may be from the blood circulation in the cancer cells. For the situation for such as skin or oral cancer in which extra PS may be applied to the cancer tissue surface to improve its efficacy. As shown by S-formulas, Eq. (5), for the anti-cancer type-II PDT efficacy S~ [O2]C, which requires both PS concentration C and [O2]. Therefore, resupply of PS or oxygen would enhance the generation of singlet oxygen radicals and improve the anti-cancer efficacy via type-II PDT. This new strategy has been proposed in type-I corneal crosslinking [13], but not yet in anti-cancer PDT. Therefore, further experimental/clinical studies are highly desired.
We have demonstrated that our formulas predict very well the measured results of Klimenko et al. [3]. However, the accuracy of our formulas will require accurate measurement of the parameters involved, such as the rate constant (K), the quantum yield (q), the molar extinction coefficient of the initiator (a’) and the photolysis product etc. In addition, further experimental measurements should also include the roles of PS concentration and light intensity. Our group has been working on the in vitro measurement of cell viability, which may be empirically analyzed by our formulas. Further study will be published elsewhere.
For the same dose, lower light intensity achieves a higher steady-state-efficacy (SSE) in type-I; in contrast to type-II, in which the efficacy is mainly dose-dependent. Type-II process is also affected by the available oxygen. Without external oxygen supply, higher light intensity produces more efficient singlet oxygen, resulting a higher transient efficacy, in which all intensities reach the same SSE when oxygen is completely depleted. With external oxygen, type-II efficacy increases with time and dose without a steady-state limitation. The overall efficacy may be enhanced by resupply of PS or oxygen during the light exposure.
This work was supported by the internal grant of New Vision Inc. KT Chen is partially supported by the Ph.D program of Graduate Institute of Applied Science and Engineering, Fu Jen Catholic University, Taiwan.
© 2018 Jui Teng Lin. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.